Celltech may abandon launch of treatment for Crohn's disease
Wednesday 31 July 2002
Celltech shareholders suffered a double blow yesterday when the company said it was considering abandoning the launch of its most advanced new drug and would halve its US salesforce.
The drug, Humicade, was being tested as a treatment for Crohn's disease, which causes inflammation of the gut, and had been expected on the market next year. But clinical trials failed to show it was effective.
The data suggests Humicade could still be useful in the treatment of acute forms of the disease, but Celltech said it would talk to US and European regulators to establish if it was likely to gain approval. Analysts predicted that, if the regulator said it would need additional trials to be carried out, the company would drop the product and concentrate development work on a second drug, CDP 870. This is a more effective product treating the same diseases as Humicade.
The company said it is to set up a specialist gastroenterology salesforce in advance of the launch of CDP 870, and that it had paid $6m to the US giant Pharmacia to license Dipentum, a treatment for an inflammatory bowel disorder which had sales of $11m in 2001.
But it is cutting its losses on Metadate, a once promising treatment for hyperactive children. The disappointing sales mean it can no longer sustain a US salesforce of 350, and this will be slashed to 170. The drug will no longer be actively marketed, and sales are unlikely to grow beyond the current $25m a year.
Metadate has struggled in the cut-throat US market for treating hyperactive children. Johnson & Johnson's Concerta has a 25 per cent market share and Shire Pharmaceuticals, the UK's number three drug company, will say later this week that it has won a 26 per cent share with its product Adderall.
Celltech shares fell more than 7 per cent to 397p.
Actress sees off speculation about her appearance in an amazing way
Powerful images of strays taken moments before being put down
The Washington Post editor helped Bob Woodward and Carl Bernstein bring down President Nixon
Children's bookseller wins The Independent's new author search
- 1 Salisbury ranked seventh-best city in the world to visit in Lonely Planet’s Best in Travel 2015
- 2 Disney announces new female-led film Moana
- 3 Banksy has not been arrested: Internet duped by fake report claiming artist's identity revealed
- 4 Kentucky gang rape: 15-year-old boy left in critical condition after sexual attack by group at party
- 5 Russell Brand threatened with arrest after filming outside Fox News headquarters
Chicago voter tells Obama 'don't touch my girlfriend' – Obama stays super smooth
Oscar Pistorius: The brutal prison life that awaits disgraced athlete
Banksy has not been arrested: Internet duped by fake report claiming artist's identity revealed
Raphael Ravenscroft dead: 'Baker Street' musician who played the most famous saxophone solo for just £27, dies aged 60
Darren Vann: Indiana man arrested for murdering teenage prostitute confesses to six other murders - and police fear more
Cameron is warned 'no possibility' of UK reducing immigration and that bid to bring in quota on migrant workers would be illegal
Residents should throw a street party and mix with immigrant neighbours, councils told
Russell Brand threatened with arrest after filming outside Fox News headquarters
London bus driver 'kicks gay couple off for kissing'
Jose Manuel Barroso warns David Cameron against making 'historic mistake' over immigration reforms
Of course, teenage girls need role models – but not like beauty vlogger Zoella
iJobs Money & Business
£18000 - £23000 per annum + Commission: SThree: The SThree group is a world le...
£18000 - £23000 per annum + Comission: SThree: The SThree group is a world lea...
£20000 - £25000 per annum + OTE £Competitive: SThree: SThree Group and have be...
£23000 per annum + pension and 22 days holiday: Ashdown Group: An established ...